Dr Jamal Zekri speaks to ecancer about his study investigating biweekly cetuximab in combination with capecitabine and oxaliplatin (XELOX) or irinotecan (XELIRI) in the first-line and second-line treatment of patients with RAS wild-type metastatic colorectal cancer.

Dr Zekri talks about the background and design of his study. He says that the study reported the tolerability and efficacy of biweekly cetuximab in combination with biweekly XELOX or XELIRI in patients with RAS wild-type metastatic colorectal cancer (RAS-WT mCRC).

The results of the study showed that biweekly cetuximab in combination with XELOX or XELIRI is effective and well tolerated.

Read the full study here.